Compare Sanofi SA (SNY) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wayfair Inc — how do they compare? Sanofi SA trades at $40 (market cap $95.18B), while Wayfair Inc trades at $105.68 (market cap $14.40B). The key difference: Sanofi SA is far larger — about 6.6× Wayfair Inc's market cap, and Sanofi SA pays a 6.01% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Wayfair Inc for 8 Days on average.
| SNY | W | |
|---|---|---|
Market Cap | $95.18B | $14.40B |
Volume | 2,995,646 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $119.05 |
52-Week Low | $39.51 | $57.40 |
Typical Hold Time | 94 Days | 8 Days |
Enterprise Value | $114.48B | $16.73B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Wayfair (W) trades at $105.70, up 1.18% today, with a bullish technical signal and strong analyst support. The stock shows positive earnings surprises in recent quarters, though it remains unprofitable with a net income margin of -2.49%. Revenue growth is modest, and the company maintains a solid gross profit margin of 30.05%. Recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook is cautiously optimistic with a consensus price target of $114.13, implying upside potential. Key risks include persistent losses, high debt-to-asset ratio, and competitive pressures. Investor sentiment is positive, but profitability challenges and macroeconomic headwinds warrant careful monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
